Helsinn Investment Fund Announces First Exit

    NEXT STORY
    Adam Kondos Wins 3rd Annual PM360 Art Attack
    PREV STORY
    Shrimp Disease Diagnostics Market Anticipated to Reach at a CAGR 6.5% during 2019-2029 – PMR
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Roche receives CHMP positive opinion for new Tecentriq-based combination therapy as an initial treatment for most common form of advanced lung cancer

    author_avatar
    NASDAQ Market News

    Calithera Biosciences Initiates a Randomized Phase 2 Combination Trial of CB-839 in Patients with Renal Cell Carcinoma

    SOUTH SAN FRANCISCO, Calif., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), ...

    author_avatar
    NASDAQ Market News

    Tempus to Participate in the NCI-MATCH Clinical Trial

    Having met rigorous qualifications, Tempus joins a select group of commercial and academic laboratories ...

    author_avatar
    NASDAQ Market News